The estimated Net Worth of Ann M. Hanly is at least 2.3 百万$ dollars as of 1 April 2024. Dr Hanly owns over 2,711 units of Vir Biotechnology Inc stock worth over 1,034,100$ and over the last 4 years he sold VIR stock worth over 339,353$. In addition, he makes 922,220$ as Exec. VP & Chief Technology Officer at Vir Biotechnology Inc.
Dr has made over 6 trades of the Vir Biotechnology Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,711 units of VIR stock worth 27,246$ on 1 April 2024.
The largest trade he's ever made was selling 12,296 units of Vir Biotechnology Inc stock on 22 February 2024 worth over 123,575$. On average, Dr trades about 2,822 units every 107 days since 2021. As of 1 April 2024 he still owns at least 132,069 units of Vir Biotechnology Inc stock.
You can see the complete history of Dr Hanly stock trades at the bottom of the page.
Dr. Ann M. Hanly Ph.D. is the Exec. VP & Chief Technology Officer at Vir Biotechnology Inc.
As the Exec. VP & Chief Technology Officer of Vir Biotechnology Inc, the total compensation of Dr D at Vir Biotechnology Inc is 922,220$. There are 7 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of 3,944,610$.
Dr D is 51, he's been the Exec. VP & Chief Technology Officer of Vir Biotechnology Inc since . There are 16 older and 5 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
Ann's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over 197,171,926$ worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth 139,246,875$ . The most active insiders traders include Norbert W Bischofberger、Endurance (Cayman) Ltd Sb I...、Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of 478,115$. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth 95,082$.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Vir Biotechnology Inc executives and other stock owners filed with the SEC include: